Dan Janney (Chairman)
Alta Partners, Managing Director
Dan Janney has been investing in life sciences companies for more than 20 years. Mr. Janney joined Alta Partners at its founding and is a Managing Director. His focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 32 companies. Prior to Alta, he was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions. Mr. Janney is currently on the board of directors of several public and private companies, including Esperion Therapeutics, Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve. In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (acquired by Cephalon), CoTherix (acquired by Actelion), DeUnity Health (acquired by United Health), Dynavax, Endonetics (acquired by Medtronic), Ilex Oncology (acquired by Millennium Pharmaceuticals), InterMune (acquired by Roche), LJL Biosystems (acquired by Molecular Devices), Mako Surgical (acquired by Stryker) and Triangle Pharmaceuticals (acquired by Gilead).
In 2006 and 2007, Mr. Janney was listed in Forbes’ Midas 100 List of Top Tech Investors. He is a member of The President’s Council of the J. David Gladstone Institutes and serves on the Board of Regents of Georgetown University. He holds a Bachelor of Arts from Georgetown University and an MBA from the Anderson School at the University of California, Los Angeles.
Robert Alexander, PhD
Chief Executive Officer
Dr. Alexander has been involved in the formation and leadership of numerous biotechnology companies. Dr. Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. Prior to ZS Pharma, Dr. Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and Allakos. Prior to Alta Partners, Robert was a Principal in MPM Capital’s BioEquities Fund. Dr. Alexander joined MPM from Genentech, where he worked in the Business Development group.
Dr. Alexander is on the Board of Directors of Allena Pharmaceuticals. He holds a PhD from the University of North Carolina at Chapel Hill and a Bachelor Science in Zoology from Miami University of Ohio.
Robert Andreatta, CFA
GOOGLE LLC, VICE PRESIDENT, CONTROLLER
Robert Andreatta has served as a member of our Board of Directors since June 2018, and has more than three decades of corporate finance and accounting experience. Mr. Andreatta has served as Vice President, Controller at Google since March 2016. Prior to Google, Mr. Andreatta was the Vice President, Controller and Chief Accounting Officer at Genentech from 2008 to 2016. Andreatta joined Genentech in 2003 as Director, Collaborations Finance, and has held positions of increasing responsibility including Director, Corporate Accounting and Reporting, Senior Director, Corporate Finance and Assistant Controller, Controller and Chief Accounting Officer. Prior to joining Genentech, Mr. Andreatta held various officer positions at HopeLink Corporation, a healthcare information technology company, and was a member of the Board of Directors of HopeLink. Prior to joining HopeLink, Mr. Andreatta was an audit partner with KPMG. Mr. Andreatta earned a Bachelor of Science degree in accounting from Santa Clara University.
President and Chief Executive Officer, Audentes Therapeutics
Ms. Holles is currently the President and Chief Executive Officer of Audentes Therapeutics (acquired by Astellas Pharma in 2020) which she joined in 2015 as Chief Operating Officer. She has more than two decades of experience in corporate development and operations leadership positions. Prior to joining Audentes, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics (acquired by Horizon Pharma). Earlier in her career, Ms. Holles served as Vice President, Business Development at KAI Pharmaceuticals (acquired by Amgen) and also held corporate development and commercial roles at InterMune and Genentech.
Ms. Holles is a member of the Board of Directors for Rubius Therapeutics. She holds a Master of Arts in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, and a Bachelor of Arts in Human Biology from Stanford University.
Steven P. James
Executive Chairman and CEO, Pionyr Immunotherapeutics
Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is president and Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Steve is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).
John P. McKearn, PhD
Managing Director, RiverVest Venture Partners
Dr. McKearn has served on Allakos’ board of directors since 2012, and has three decades of drug development and investing experience in life sciences. Dr. McKearn has been with RiverVest since 2008 and focuses primarily on early-stage biotechnology investments. Prior to RiverVest, Dr. McKearn was president and CEO of Kalypsys. From 1987 to 2003, Dr. McKearn held increasingly responsible positions at Searle/Pharmacia, including Senior VP of Research. He helped establish the groundwork for studies that led to the commercialization of several major products, including DayPro, Arthrotec, and Celebrex, one of the leading pharmaceuticals to treat arthritis. Prior to 1987, Dr. McKearn was a senior scientist at E.I. DuPont de Nemours and Company, a member of the Basel Institute for Immunology in Basel, Switzerland, and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis.
Dr. McKearn is also on the boards of OncoResponse, Good Therapeutics, Arch Oncology and Adarza Biosystems. He previously served on the boards of IDM Pharma (acquired by Takeda), Epimmune, Kalypsys, Keel Pharmaceuticals, Lumena Pharmaceuticals (acquired by Shire), Otonomy and ZS Pharma (acquired by Astra Zeneca). Dr. McKearn he has co-authored more than 70 published, peer-reviewed scientific papers, and holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease. Dr. McKearn holds a PhD in Immunology from the University of Chicago and a Bachelor of Science in Biology from Northern Illinois University.
Paul Walker, CFA
NEW ENTERPRISE ASSOCIATES, PARTNER
Paul Walker has more than 20 years of life sciences investing experience. Mr. Walker has been a Partner at New Enterprise Associates, an investment firm focused on venture capital and growth equity investments, since 2008. He focuses on later-stage biotechnology and life sciences investments. In 2001, Mr. Walker joined MPM Capital and was a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Mr. Walker received a Bachelor of Science in Biochemistry and Cell Biology from the University of California at San Diego, and holds the Chartered Financial Analyst designation.